Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors

Phase 1

• Conditions: Gastrointestinal Cancer; Bile Duct Carcinoma; Esophageal Carcinoma; Colorectal Adenocarcinoma; Gastric Adenocarcinoma; Pancreatic Adenocarcinoma; Hepatocellular Carcinoma
• Interventions: Drug: CGX1321

• Registration Number: NCT03507998
• Lead Sponsor: Curegenix Inc.

Brief Summary

This is a multi-center, open label, repeat dose, Phase 1 study consisting of a Dose Escalation Phase and a Dose Expansion Phase to evaluate safety, pharmacokinetics, and clinical activity.

Detailed Description

The purpose of the Dose Escalation Phase is to examine the safety and determine the maximum tolerated dose of CGX1321 when administered to subjects with advanced GI tumors that have relapsed or are refractory to or not considered medically suitable to receive standard of care treatment.

Once the dose is identified in the Dose Escalation Phase, the Dose Expansion Phase will start. The purpose of the Dose Expansion Phase is to continue to examine the safety and confirm the final Phase 2 dose of CGX1321 when administered to subjects with advanced GI tumors who meet the entry criteria.

Study Timeline

• Study Start: 2017-06-17
• Study First Submitted: 2018-04-16
• Study First Submitted QC: 2018-04-16
• Study First Posted: 2018-04-25
• Status Verified: 2020-07
• Last Update Submitted: 2020-07-22
• Last Update Posted: 2020-07-24
• Primary Completion: 2021-04-01
• Study Completion: 2021-04-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 39

Inclusion Criteria

• Histologically-diagnosed advanced Gl tumors, such as colorectal adenocarcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma, bile duct carcinoma, hepatocellular carcinoma, esophageal carcinoma that have relapsed or are refractory to or are not considered medically suitable to receive standard of care treatment
• Eastern Cooperative Oncology Group (ECOG) score of 0 - 1
• Minimum estimated life expectancy of 3 months
• Adequate organ function
• Recovery from prior treatment-related toxicities
• Ability to swallow capsules
• Willingness for subjects of reproductive potential to use adequate methods of contraception during and for 3 months after study treatment

Exclusion Criteria

• Prior exposure to a WNT inhibitor
• Received previous therapy for malignancy within 21 days
• Major surgery within 4 weeks of first dose of study drug
• Radiotherapy within 2 weeks of first dose of study drug
• Significant GI or variceal bleeding or subdural hematoma within 3 months of treatment start
• Uncontrolled central nervous system metastases or leptomeningeal metastases
• Requirement for immunosuppressive agents (must be off for at least 7 days)
• Currently receiving medications that are known CYP3A4/5 inhibitors. Patients currently receiving medications of known inducers of CYP3A4/5 or substrates of CYP2C8/9 and CYP1A2 may be excluded.
• Bone abnormalities
• Hypercalcemia
• Cardiac abnormalities
• Known human immunodeficiency virus positive, or active hepatitis A, B or C
• History of additional prior malignancy with the exception of surgically cured carcinomas such as skin, prostate, bladder, thyroid, cervix or other carcinomas in situ
• Active systemic infection requiring intravenous antibiotics within 2 weeks of treatment start
• Pregnancy or lactation

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
CGX1321 Dosing	CGX1321	Dose Escalation Phase: Ascending doses of CGX1321 will be administered by cohort to determine the maximum tolerated dose. Patients will receive CGX1321, once daily, orally, for 3 weeks (21 days) followed by a one week (7 day) washout period in each 28 day cycle, according to the cohort they are assigned. Dose Expansion Phase: Patients will receive the recommended dose (identified in the Dose Expansion Phase) of CGX1321

Primary Outcome Measures

Name	Time	Method
Number of participants with adverse events and/or abnormal laboratory values that are related to treatment	21 months

Secondary Outcome Measures

Name	Time	Method
CGX1321 maximum or peak concentration	30 days
CGX1321 minimum or trough concentration	30 days
CGX1321 time to maximum concentration	30 days
CGX1321 half life	30 days

Trial Locations

Locations (2)

Beijing Cancer Hospital; 🇨🇳 Beijing, China

Cancer Institute and Hospital, Chinese Academy of Medical Sciences; 🇨🇳 Beijing, China